Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] gained 4.59% on the last trading session, reaching $1.14 price per share at the time. The company report on July 27, 2020 that Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC.
Guidance being incorporated into global study protocolEnrollment of first patient now expected in August.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced receipt of guidance from the U.S. Food and Drug Administration (FDA) on the Company’s recently-filed Investigational New Drug (IND) application for trans sodium crocetinate (TSC) in COVID-19 patients. This guidance suggests certain study design changes with regard to endpoints and statistical considerations that Diffusion believes will enhance the prospect of regulatory approvals upon program completion, should the clinical results be favorable.
Diffusion Pharmaceuticals Inc. represents 59.63 million in outstanding shares, while the company has a total market value of $70.38 million with the latest information. DFFN stock price has been found in the range of $1.07 to $1.15.
If compared to the average trading volume of 6.51M shares, DFFN reached a trading volume of 1158545 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Diffusion Pharmaceuticals Inc. [DFFN]:
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 21, 2018.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.12 The Price to Book ratio for the last quarter was 2.19, with the Price to Cash per share for the same quarter was set at 0.17.
Trading performance analysis for DFFN stock
Diffusion Pharmaceuticals Inc. [DFFN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.54. With this latest performance, DFFN shares gained by 25.27% in over the last four-week period, additionally plugging by 170.27% over the last 6 months – not to mention a drop of -46.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 50.32, with the RSI for the last a single of trading hit 49.12, and the three-weeks RSI is set at 52.48 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 1.0894, while it was recorded at 1.1440 for the last single week of trading, and 0.6591 for the last 200 days.
Diffusion Pharmaceuticals Inc. [DFFN]: A deeper dive into fundamental analysis
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.10 and a Current Ratio set at 9.10.
Diffusion Pharmaceuticals Inc. [DFFN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.63/share EPS, while the average EPS was predicted by analysts to be reported at -0.69/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 8.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
An analysis of insider ownership at Diffusion Pharmaceuticals Inc. [DFFN]
There are presently around $4 million, or 8.50% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,679,187, which is approximately 121.443% of the company’s market cap and around 0.23% of the total institutional ownership; BLACKROCK INC., holding 820,779 shares of the stock with an approximate value of $0.94 million in DFFN stocks shares; and ACADIAN ASSET MANAGEMENT LLC, currently with $0.43 million in DFFN stock with ownership of nearly 52.515% of the company’s market capitalization.
12 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 1,247,206 shares. Additionally, 6 investors decreased positions by around 1,361,141 shares, while 8 investors held positions by with 736,975 shares. The mentioned changes placed institutional holdings at 3,345,322 shares, according to the latest SEC report filing. DFFN stock had 6 new institutional investments in for a total of 152,427 shares, while 2 institutional investors sold positions of 1,095,446 shares during the same period.